Subscribe
shutterstock_1506315968_sleepingpanda-1
sleepingpanda / Shutterstock.com
20 April 2021BiotechnologyThomas Moga

The curious case of Wuhan’s Institute of Virology and remdesivir

The Patent Law of the People’s Republic of China first went into effect on April 1, 1985. It has been amended three times with a fourth amendment scheduled to take effect on June 1, 2021.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Campaigners say US govt should have remdesivir patent rights
28 May 2020   The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.
Asia
Indian police seize black market remdesivir, arrest 14
21 July 2020   Police in Mumbai and Hyderabad have arrested 14 people on suspicion of distributing black market remdesivir at five times its retail price.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Campaigners say US govt should have remdesivir patent rights
28 May 2020   The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.
Asia
Indian police seize black market remdesivir, arrest 14
21 July 2020   Police in Mumbai and Hyderabad have arrested 14 people on suspicion of distributing black market remdesivir at five times its retail price.

More on this story

Americas
Campaigners say US govt should have remdesivir patent rights
28 May 2020   The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.
Asia
Indian police seize black market remdesivir, arrest 14
21 July 2020   Police in Mumbai and Hyderabad have arrested 14 people on suspicion of distributing black market remdesivir at five times its retail price.

More features

China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar